OpenAI Acquires Orchestra Bio

OpenAI has acquired the drug development collaboration platform Orchestra Bio. This platform helps biopharmaceutical teams coordinate the drug development process, allowing scientists and project leaders to delegate the monitoring and tracking of research and trials to AI agents. OpenAI will integrate the Orchestra team and technology with its life sciences research AI model and tools, Rosalind, to accelerate the development of new therapies and benefit patients.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.